Mammalian models of bone sarcomas

[1]  T. Fujiwara,et al.  Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma , 2020, Cancer Immunology, Immunotherapy.

[2]  C. H. Nielsen,et al.  Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis , 2020, Scientific Reports.

[3]  E. Kleinerman,et al.  Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma , 2020, International journal of cancer.

[4]  M. Chang,et al.  A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression , 2020, Nature Communications.

[5]  Nicholas J. Slipek,et al.  Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma , 2020, Molecular Cancer Therapeutics.

[6]  M. Durante,et al.  Reduction of lung metastases in a mouse osteosarcoma model treated with carbon ions and immune checkpoint inhibitors. , 2020, International journal of radiation oncology, biology, physics.

[7]  Lang Li,et al.  Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma , 2020, Cancers.

[8]  B. Teicher,et al.  Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium , 2020, Pediatric hematology and oncology.

[9]  B. Teicher,et al.  Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium , 2020, Pediatric blood & cancer.

[10]  Haydee M Torres,et al.  Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway , 2020, Oncotarget.

[11]  D. Reed,et al.  Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma , 2020, International journal of cancer.

[12]  Yuanzhong Wu,et al.  Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma , 2020, Theranostics.

[13]  A. Yamamoto,et al.  Promising abscopal effect of combination therapy with thermal tumour ablation and intratumoural OK-432 injection in the rat osteosarcoma model , 2020, Scientific Reports.

[14]  C. Isella,et al.  Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights , 2020, Cancers.

[15]  P. Houghton,et al.  Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium , 2020, Pediatric blood & cancer.

[16]  S. Dry,et al.  Patient-derived orthotopic xenograft models of sarcoma. , 2020, Cancer letters.

[17]  M. Heymann,et al.  Bone sarcomas in the immunotherapy era , 2020, British journal of pharmacology.

[18]  M. Martano,et al.  In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models. , 2019, Veterinary and comparative oncology.

[19]  I. Alferiev,et al.  Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS‐2/8 Chondrosarcoma Cells , 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[20]  D. Haussler,et al.  Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design , 2019, Cell reports.

[21]  B. Fuchs,et al.  The miR‐143/145 Cluster, a Novel Diagnostic Biomarker in Chondrosarcoma, Acts as a Tumor Suppressor and Directly Inhibits Fascin‐1 , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  J. Webster,et al.  Applications and considerations for the use of genetically engineered mouse models in drug development , 2019, Cell and Tissue Research.

[23]  G. R. Ordóñez,et al.  New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth , 2019, Journal of clinical medicine.

[24]  D. Heymann,et al.  Jaw osteosarcoma models in mice: first description , 2019, Journal of Translational Medicine.

[25]  R. Oyama,et al.  Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1 , 2019, Human Cell.

[26]  Shing-Hwa Liu,et al.  MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis , 2018, International journal of molecular sciences.

[27]  Marcus R. Breese,et al.  Genome-Informed Targeted Therapy for Osteosarcoma. , 2018, Cancer discovery.

[28]  P. Houghton,et al.  Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling , 2018, Clinical Cancer Research.

[29]  M. Heymann,et al.  Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy , 2018, Journal of bone oncology.

[30]  S. Kizaka-Kondoh,et al.  Novel lymphoid enhancer‐binding factor 1‐cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs , 2018, Cancer science.

[31]  M. Symons,et al.  Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model of Metastasis: A Mouse Osteosarcoma Model , 2018, Clinical orthopaedics and related research.

[32]  A. Boccaccini,et al.  Proangiogenic effects of tumor cells on endothelial progenitor cells vary with tumor type in an in vitro and in vivo rat model , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  C. Chenu,et al.  Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A , 2018, Scientific Reports.

[34]  J. M. Guimarães,et al.  PATIENT-DERIVED XENOGRAFTS AS A PRECLINICAL MODEL FOR BONE SARCOMAS , 2018, Acta ortopedica brasileira.

[35]  D. Heymann,et al.  Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations , 2018, Journal of bone oncology.

[36]  M. Heymann,et al.  Biology of Bone Sarcomas and New Therapeutic Developments , 2017, Calcified Tissue International.

[37]  Jinhu Liu,et al.  Redox‐sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[38]  T. Nakagawa,et al.  Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model. , 2017, Research in veterinary science.

[39]  D. Heymann,et al.  Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. , 2017, Cancer letters.

[40]  B. Fuchs,et al.  Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models , 2017, International journal of cancer.

[41]  T. Nakagawa,et al.  Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines. , 2016, Veterinary journal.

[42]  L. Donehower,et al.  Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential , 2016, BMC Cancer.

[43]  G. Mælandsmo,et al.  Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma , 2016, PloS one.

[44]  Kevin B. Jones,et al.  Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis , 2016, Disease Models & Mechanisms.

[45]  M. Heymann,et al.  Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.

[46]  K. Condon,et al.  Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats , 2016, PloS one.

[47]  D. Surdez,et al.  Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model , 2016, Oncotarget.

[48]  D. Saur,et al.  A porcine model of osteosarcoma , 2016, Oncogenesis.

[49]  Kyle W. Jackson,et al.  An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis , 2015, Clinical & Experimental Metastasis.

[50]  Kevin B. Jones,et al.  Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency , 2015, The Journal of pathology.

[51]  D. Heymann,et al.  BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma , 2015, International journal of cancer.

[52]  P. Yuan,et al.  Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression , 2014, Oncogene.

[53]  Kevin B. Jones,et al.  The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse , 2014, Oncogene.

[54]  B. Dawson,et al.  Notch activation as a driver of osteogenic sarcoma. , 2014, Cancer cell.

[55]  D. Meyerholz,et al.  Development and translational imaging of a TP53 porcine tumorigenesis model. , 2014, The Journal of clinical investigation.

[56]  Ranim R. Mira,et al.  Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model. , 2014, American journal of cancer research.

[57]  David Sidransky,et al.  Patient-derived xenografts for individualized care in advanced sarcoma , 2014, Cancer.

[58]  Frederic Blanchard,et al.  Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models , 2014, PloS one.

[59]  A. Chalk,et al.  Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. , 2013, Bone.

[60]  F. Verrecchia,et al.  A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis. , 2013, European journal of cancer.

[61]  M. Heymann,et al.  New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance , 2013, Laboratory Investigation.

[62]  M. Mochizuki,et al.  Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice. , 2012, Veterinary and comparative oncology.

[63]  O. Delattre,et al.  Oncostatin M is a growth factor for Ewing sarcoma. , 2012, The American journal of pathology.

[64]  J. Blay,et al.  Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model , 2012, PloS one.

[65]  D. Jong,et al.  Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT , 2012, Oncogene.

[66]  A. Llombart‐Bosch,et al.  Characterization of a New Human Cell Line (CH-3573) Derived from a Grade II Chondrosarcoma with Matrix Production , 2012, Pathology & Oncology Research.

[67]  J. Chezal,et al.  Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma. , 2012, Cancer biotherapy & radiopharmaceuticals.

[68]  G. Moriceau,et al.  Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. , 2010, Cancer research.

[69]  A. Constantinesco,et al.  Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. , 2010, Translational oncology.

[70]  O. Delattre,et al.  Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. , 2010, Cancer research.

[71]  T. Triche,et al.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. , 2010, The Journal of clinical investigation.

[72]  J. Monteil,et al.  18F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model , 2009, Journal of Nuclear Medicine.

[73]  P. Lin,et al.  EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. , 2008, Cancer research.

[74]  M. Bouxsein,et al.  Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage , 2008, Proceedings of the National Academy of Sciences.

[75]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[76]  Mimi Kim,et al.  Preclinical Analysis of Tasidotin HCl in Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, and Osteosarcoma , 2007, Clinical Cancer Research.

[77]  C. Nanni,et al.  Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.

[78]  D. Heymann,et al.  Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival , 2006, International journal of cancer.

[79]  M. Heymann,et al.  Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.

[80]  J. Thiery,et al.  Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. , 2005, Bone.

[81]  E. Kleinerman,et al.  Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo , 2005, Clinical Cancer Research.

[82]  D. Heymann,et al.  Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. , 2002, Histology and histopathology.

[83]  H. Jürgens,et al.  Establishment of an In Vivo Model for Pediatric Ewing Tumors by Transplantation into NOD/ scid Mice , 2001, Pediatric Research.

[84]  A. Dietz,et al.  Production and characterization of canine osteosarcoma cell lines that induce transplantable tumors in nude mice. , 1998, American journal of veterinary research.

[85]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[86]  E. Wagner,et al.  Osteoblasts are target cells for transformation in c-fos transgenic mice , 1993, The Journal of cell biology.

[87]  K. Gomi,et al.  ANTITUMOR EFFECT OF HUMAN RECOMBINANT INTERFERON-γ AND -β AGAINST HUMAN OSTEOSARCOMA TRANSPLANTED INTO NUDE MICE , 1986 .